

# Ronald Andrew Seaton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3597034/publications.pdf>

Version: 2024-02-01

37  
papers

2,273  
citations

331670

21  
h-index

377865

34  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2857  
citing authors

#	ARTICLE	IF	CITATIONS
1	Co-infections and antimicrobial use among hospitalized COVID-19 patients in Punjab, Pakistan: findings from a multicenter, point prevalence survey. <i>Pathogens and Global Health</i> , 2022, 116, 421-427.	2.3	22
2	Outpatient parenteral antimicrobial therapy (OPAT) in the UK: findings from the BSAC National Outcomes Registry (2015-19). <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1481-1490.	3.0	17
3	P15 Evaluation of the stability of temocillin in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy in accordance with the requirements of the UK NHS Yellow Cover Document. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, .	2.1	0
4	Survey of delivery of parenteral antimicrobials in non-inpatient settings across Europe. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106559.	2.5	5
5	Associations between declining antibiotic use in primary care in Scotland and hospitalization with infection and patient satisfaction: longitudinal population study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2561-2568.	3.0	2
6	A multicentre point prevalence survey of hospital antibiotic prescribing and quality indices in the Kurdistan regional government of Northern Iraq: the need for urgent action. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 805-814.	4.4	23
7	Recent innovations and new applications of outpatient parenteral antimicrobial therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 55-64.	4.4	10
8	Antibiotic prescribing for respiratory tract infection in patients with suspected and proven COVID-19: results from an antibiotic point prevalence survey in Scottish hospitals. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab078.	2.1	6
9	Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab141.	2.1	9
10	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , The, 2021, 2, e354-e365.	7.3	216
11	Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses. <i>BMJ Open</i> , 2021, 11, e049733.	1.9	26
12	Antibiotic use towards the end of life: development of good practice recommendations. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjpspcare-2020-002732.	1.6	4
13	Assessment of the stability of citrate-buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements. <i>European Journal of Hospital Pharmacy</i> , 2020, , eihpharm-2020-002340.	1.1	11
14	Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. <i>Journal of Infection</i> , 2020, 81, 952-960.	3.3	79
15	Mechanisms affecting the implementation of a national antimicrobial stewardship programme; multi-professional perspectives explained using normalisation process theory. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 99.	4.1	13
16	Antimicrobial use at the end of life: a scoping review. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjpspcare-2020-002558.	1.6	3
17	Antimicrobial point prevalence surveys in two Ghanaian hospitals: opportunities for antimicrobial stewardship. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa001.	2.1	53
18	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in East Africa: red alert or red herring?. <i>BMC Infectious Diseases</i> , 2019, 19, 596.	2.9	48

#	ARTICLE	IF	CITATIONS
19	Outpatient parenteral antimicrobial therapy: updated recommendations from the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3125-3127.	3.0	27
20	Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. <i>JAC-Antimicrobial Resistance</i> , 2019, 1, dlz026.	2.1	58
21	Oral versus Intravenous Antibiotics for Bone and Joint Infection. <i>New England Journal of Medicine</i> , 2019, 380, 425-436.	27.0	548
22	Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-92.	2.8	27
23	Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections. <i>Infection and Drug Resistance</i> , 2016, 9, 47.	2.7	54
24	Late Ebola virus relapse causing meningoencephalitis: a case report. <i>Lancet</i> , The, 2016, 388, 498-503.	13.7	291
25	Comparative healthcare-associated costs of methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia-infective endocarditis treated with either daptomycin or vancomycin. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 357-361.	2.5	6
26	Antimicrobial stewardship in wound care: a Position Paper from the British Society for Antimicrobial Chemotherapy and European Wound Management Association. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3026-3035.	3.0	117
27	Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 18.	3.8	37
28	Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin® Outcomes Registry and Experience. <i>Advances in Therapy</i> , 2015, 32, 1192-1205.	2.9	54
29	Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 305-311.	2.9	15
30	Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 468-472.	2.5	23
31	Outpatient parenteral antibiotic therapy: Principles and practice. <i>European Journal of Internal Medicine</i> , 2013, 24, 617-623.	2.2	71
32	Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORESM database. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1642-1649.	3.0	40
33	Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1053-1062.	3.0	165
34	Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 243-248.	2.5	70
35	Clinical experience with daptomycin in Europe: the first 2.5 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 912-919.	3.0	72
36	Bio-hazards and drug reactions: A cautionary tale. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 312-313.	1.5	2

#	ARTICLE	IF	CITATIONS
37	Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 764-767.	3.0	49